AngioDynamics appointed Eric Honroth as President and Chief Executive Officer and a member of its Board of Directors, effective November 2, 2026. Honroth will succeed Jim Clemmer, who is retiring after 10 years as President and CEO.
Clemmer will leave the board on November 2 but remain with the medical technology company in a consulting capacity to support the transition.
The appointment follows a board-led search focused on identifying a leader with medical technology experience, commercial execution capabilities, and a record of improving operational performance.
Honroth brings more than 20 years of leadership experience across medical devices and life sciences.
His industry experience spans cardiovascular, endovascular, urology, and oncology markets, aligning closely with AngioDynamics’ portfolio.
Most recently, Honroth served as Global President of Life Science at Getinge.
He previously led Getinge’s approximately $1.2 billion North American business.
During his tenure, Honroth worked on accelerating growth, expanding revenue, developing new products, managing the company’s portfolio, and strengthening commercial operations.
Earlier in his career, he held senior leadership positions at Abbott Vascular, Becton Dickinson, CareFusion, and Boston Scientific.
His experience includes responsibility for large commercial organizations and global operations across both revenue growth and cost management.
AngioDynamics said Honroth will build on the company’s recent transformation and focus on sustainable revenue growth, margin expansion, and long-term shareholder value.
The company highlighted the strength of its growing Med Tech segment, differentiated technology portfolio, and debt-free balance sheet as foundations for the next phase of its strategy.
KEY QUOTES:
“AngioDynamics enters this transition with real momentum, including a high-growth Med Tech segment, a strong balance sheet with no outstanding debt, and an operational transformation that is delivering.”
Howard Donnelly, Board Chair of AngioDynamics
“Eric has done what this moment requires. He has built businesses, driven profitable growth, and managed global operations with responsibility for both revenue and cost structure.”
Howard Donnelly, Board Chair of AngioDynamics
“The Company has a differentiated technology portfolio, multiple growth drivers, and an exceptionally talented team. I look forward to working with employees and customers to build on this foundation and accelerate progress where we see the greatest opportunities to improve patient care and create shareholder value.”
Eric Honroth, Incoming President and CEO of AngioDynamics
“Together, we sharpened the Company’s focus, expanded operating capabilities, and positioned the business for its next phase of growth.”
Jim Clemmer, President and CEO of AngioDynamics
